clinical trial · NCT04702568
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Nocturnal HemoglobinuriaPNHBCX9930EculizumabRavulizumab
brief summary
This study was designed to evaluate the long-term safety of daily oral treatment with BCX9930 in participants who had participated in a previous BCX9930 trial for PNH and showed a benefit of treatment as determined by the Investigator. The study allowed continued access to BCX9930 for enrolled participants. The study also evaluated the long-term effectiveness and impact on quality of life and general well-being of BCX9930 treatment, and the participant's satisfaction with the medication.
started
Dec 18, 2020
primary completion
Oct 4, 2023
completion
Oct 4, 2023
last updated
Apr 13, 2025
official title
A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol